Alzheimer's Disease and Immunotherapy

被引：0
作者：
Madeo, Jennifer [1 ]
Frieri, Marianne [1 ]
机构：
[1] Nassau Univ, Med Ctr, Dept Med, E Meadow, NY 11554 USA
来源：
AGING AND DISEASE | 2013年 / 4卷 / 04期
关键词：
Alzheimer's disease; immunotherapy; immunosenescence; vaccination; monoclonal antibodies; AMYLOID-BETA IMMUNOTHERAPY; CENTRAL-NERVOUS-SYSTEM; A-BETA; COGNITIVE IMPAIRMENT; MOUSE MODEL; PASSIVE IMMUNOTHERAPY; TRANSGENIC MOUSE; CLINICAL-TRIALS; DOUBLE-BLIND; MEMORY LOSS;
D O I：
暂无
中图分类号：
R592 [老年病学]; C [社会科学总论];
学科分类号：
03 ; 0303 ; 100203 ;
摘要：
Alzheimer's disease (AD) is a growing health care epidemic. It is the most common cause of dementia and its incidence is rising. Age, which influences the oxidative and inflammatory states of the brain, is the most important risk factor. Currently there is no disease modifying treatments available for this irreversible, progressive debilitating disease. Immunotherapy represents an emerging, potentially disease modifying strategy aimed at reducing the pathological lesions of AD and facilitating cognitive improvement. Many clinical trials are currently underway. This literature review highlights current knowledge regarding the physiology of aging and how it relates to the pathogenesis of AD. In addition, immunotherapy is discussed in the context of its mechanism, current studies and future goals.
引用
收藏
页码：210 / 220
页数：11
相关论文
共 89 条
[21]   Safety and biomarker effects of Solanezumab in patients with Alzheimer's disease [J].
Farlow, Martin ;
Amold, Steven E. ;
van Dyck, Christopher H. ;
Aisen, Paul S. ;
Snider, B. Joy ;
Porsteinsson, Anton P. ;
Friedrich, Stuart ;
Dean, Robert A. ;
Gonzales, Celedon ;
Sethuraman, Gopalan ;
DeMattos, Ronald B. ;
Mohs, Richard ;
Paul, Steven M. ;
Siemers, Eric R. .
ALZHEIMERS & DEMENTIA, 2012, 8 (04) :261-271
[22]   Contribution of complement activation pathways to neuropathology differs among mouse models of Alzheimer's disease [J].
Fonseca, Maria I. ;
Chu, Shu-Hui ;
Berci, Alisia M. ;
Benoit, Marie E. ;
Peters, Douglas G. ;
Kimura, Yuko ;
Tenner, Andrea J. .
JOURNAL OF NEUROINFLAMMATION, 2011, 8
[23]   Effects of Aβ immunization (AN1792) on MRI measures of cerebral volume in Alzheimer disease [J].
Fox, NC ;
Black, RS ;
Gilman, S ;
Rossor, MN ;
Griffith, SG ;
Jenkins, L ;
Koller, M .
NEUROLOGY, 2005, 64 (09) :1563-1572
[24]   39-Week Toxicity and Toxicokinetic Study of Ponezumab (PF-04360365) in Cynomolgus Monkeys with 12-Week Recovery Period [J].
Freeman, Gary B. ;
Lin, John C. ;
Pons, Jaume ;
Raha, Nancy M. .
JOURNAL OF ALZHEIMERS DISEASE, 2012, 28 (03) :531-541
[25]   Amyloid-β Immunotherapy for Alzheimer's Disease [J].
Fu, H. J. ;
Liu, B. ;
Frost, J. L. ;
Lemere, C. A. .
CNS & NEUROLOGICAL DISORDERS-DRUG TARGETS, 2010, 9 (02) :197-206
[26]   Central nervous system inflammation in disease related conditions: Mechanistic prospects [J].
Fung, Anthony ;
Vizcaychipi, Marcela ;
Lloyd, Dafydd ;
Wan, Yanjie ;
Ma, Daqing .
BRAIN RESEARCH, 2012, 1446 :144-155
[27]  
Ghochikyan A, 2013, HUM VACCIN IMMUNOTHE, V9
[28]   Immunosenescence and infectious diseases [J].
Ginaldi, L ;
Loreto, MF ;
Corsi, MP ;
Modesti, M ;
De Martinis, M .
MICROBES AND INFECTION, 2001, 3 (10) :851-857
[29]  
Glat MJ, 2013, STEM CELLS DEV
[30]   Age and Neuroinflammation: A Lifetime of Psychoneuroimmune Consequences [J].
Godbout, Jonathan P. ;
Johnson, Rodney W. .
IMMUNOLOGY AND ALLERGY CLINICS OF NORTH AMERICA, 2009, 29 (02) :321-+
123456789